Zurich Biotech Company Vaccentis Opens EU Hub in Vienna
21.10.2025 | from Panta Rhei PR
Reading time: 3 minutes
21.10.2025, The Swiss biotechnology company Vaccentis has achieved a significant milestone with the opening of its new branch in Vienna. The new location in the Biotech Cluster Seestadt in Vienna-Donaustadt will serve as the central EU competence center for all research and development activities and the related regulatory activities. A particular focus is on preparing for the approval of the innovative therapeutic cancer vaccine VCC-001 with the European Medicines Agency (EMA).
“Vaccentis stands for individualized immunotherapy against cancer. Our further expansion to Vienna – one of the largest European biotech centers – is a strategic step to lead our development programs purposefully and efficiently to European approval,” explains Ingrid Rauter, Head of Research & Development and Chief Medical Officer at Vaccentis. Zurich will continue to serve as our central corporate headquarters. At the same time, we see the Austrian capital as a strategic bridgehead into the EU – at a time when scientific excellence, regulatory agility, and trusted partnerships are crucial to bring innovation of high quality and faster to patients.
EU Hub Austria The Vienna location will serve as the scientific headquarters for the coordination of all research and development activities as well as the associated regulatory interactions within the EU, and the further development of scientific partnerships. “We deliberately chose Vienna as our EU location due to its central position in the European Union and the existing local expertise in order to efficiently steer our activities in one of the largest economic areas in the world. Furthermore, we intend to expand our investments not only in Switzerland, our home market strongly focused on the health sector, but also in Austria to advance the development of our innovative therapeutic cancer vaccine VCC-001 and thus make a significant contribution to the forthcoming market introduction,” explains Vaccentis-CEO Martin Munte.
The Logical Alternative: New Approach to Cancer Therapy Vaccentis has specialized in a new approach to cancer therapy: individualized medicine. The company is currently developing a protein-based therapeutic cancer vaccine while other competitors focus on mRNA. With Vaccentis’ approach, patients’ own tissue is extracted, purified, and an individualized vaccine is developed, which aims to prevent the progression of the disease.
The cancer vaccine VCC-001 is currently being developed for the adjuvant treatment of renal cell carcinoma, with other indications to follow. In earlier clinical studies, VCC-001 has shown effectiveness and a good side effect profile as well as improved patient quality of life. Based on multi-year clinical data, VCC-001 is to be submitted for market approval to the EMA, the US Food and Drug Administration (FDA), and Swissmedic by the end of this decade.
Contact
Vaccentis AG
Martin Munte, Chief Executive Officer
Email: info@vaccentis.ch; Phone: +41 79 428 22 97
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « Zurich Biotech Company Vaccentis Opens EU Hub in Vienna »
Panta Rhei PR
Vaccentis AG is a company focused on the biotech and pharma sector, headquartered in Zurich. The Swiss pharmaceutical company specializes in the development and production of individualized cancer vaccines.
The focus is primarily on the development of therapeutic vaccines manufactured from patients’ own tumors – initially against renal cell carcinoma, with further indications to follow. Approval for the EU and US markets is expected in the upcoming years. At the helm of Vaccentis is a leadership team with years of experience, including CEO Martin Munte and Head of Research Ingrid Rauter.
Note: The "About Us" text is taken from public sources or from the company profile on HELP.ch.
Source: Panta Rhei PR, Press release
Original article published on: Zürcher Biotech-Unternehmen Vaccentis eröffnet EU-Hub in Wien